Pre-Cure develops the most advanced functional ex-vivo predictive platforms in oncology, enabling accurate predictions of treatment response outside the body and ensuring that cancer patients receive the most effective therapy
‍from the very first line.

In parallel, we collaborate with pharmaceutical companies to accelerate and de-risk preclinical drug candidates. Our innovations are powered by bio-convergence technologies, integrating biology- tumour modelling and 3D cell cultures with engineering, including 3D-printed biomimetic devices and nanoparticles.